Druck Icon

Eckert & Ziegler to Host First Radionuclide Theranostics Forum in Boston, MA

BOSTON, Mass., May 30, 2023 – By organizing the first Boston Radionuclide Theranostics Forum and bringing together numerous renowned experts in Boston, Mass., Eckert & Ziegler underscores its leading position in the field of radiopharmaceuticals. On June 1st, 2023, the company will connect potential and existing partners as well as key industry players to dive into a vigorous discussion on the central topics of the rapidly developing radiotheranostics market. The Forum will discuss solutions to challenges in supply chain, upscaling and patient access as well as the latest theranostic concepts.

“We are excited to host the first edition of the Radionuclide Theranostics Forum in Boston and to bring together leading experts in the field of radiotheranostics. The event will build on the momentum of recent developments and approvals and foster discourse on current and future challenges," said Dr. Harald Hasselmann, Executive Director and responsible for the Medical segment of Eckert & Ziegler. “More than three decades of experience in handling and manufacturing radiopharmaceuticals and radioactive medical devices, developing technical solutions and processes, enable us to fully assess and support concepts and thus facilitate partner projects. We are confident that many of the ideas generated together during our Forum will be an important foundation for the development of precision oncology in North America and globally in the years to come."

The Boston Radionuclide Theranostics Forum is initiated and sponsored by Eckert & Ziegler and organized together with the support of the German-American Business Council of Boston (GABC). The half-day event will be hosted at the Boston offices of the international law firm Morrison & Foerster LLP. More than a dozen international experts and executives from clinic, industry, research and beyond are scheduled to speak in panel discussions and fireside chats. Attendance is by invitation only and is at capacity.

About Eckert & Ziegler.
Eckert & Ziegler Strahlen- und Medizintechnik AG with more than 1,000 employees is a leading specialist for isotope-related components in nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
Contributing to saving lives.

Eckert & Ziegler AG
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Karolin Riehle, Investor Relations / Jan Schöpflin, Marketing
karolin.riehle@ezag.de / jan.schoepflin@ezag.de
Tel.: +49 (0) 30 / 94 10 84-138; www.ezag.com


30.05.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

Language: English
Company: Eckert & Ziegler Strahlen- und Medizintechnik AG
13125 Berlin
Phone: +49 30 941084-138
Fax: +49 30 941084-112
E-mail: karolin.riehle@ezag.de
Internet: www.ezag.de
ISIN: DE0005659700
WKN: 565970
Indices: SDAX, TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1643195

End of News EQS News Service

show this